MedTrace Logo

Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia

NCT04655235 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-03-14

No results posted yet for this study

Summary

In the last years, the imbalance between excitatory and inhibitory neuronal activity has come to the fore as a possible molecular disease mechanism of schizophrenia . Pharmacological studies have suggested different fMRI and EEG markers of that molecular dysfunction (resting state connectivity changes, auditory mismatch and steady state deficits). However, previous research is inconclusive regarding their genetic basis, their reliability, inter-individual relationship as well as disease specificity. Therefore, in this study we aim at estimating the effect sizes, test-retest-reliability and clinical correlates of the respective markers in a comparative fashion in patients with schizophrenia, their relatives and healthy control subject. To assess their molecular validity, we will assess their relationship with glutamatergic and GABAergic genotypes and cellular disease models. The proof of such a relation would give the opportunity of detecting a glutamatergic and GABAergic imbalance throughout non-invasive imaging. Furthermore, it would help deepening our understanding of the molecular pathophysiology of mental disorders which will be essential for the development of more effective drugs.

Conditions

Interventions

GENETIC

Genotyping

Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Arnim Gaebler, M.D. · Uniklinik RWTH Aachen

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2028-12-31
Completion
2030-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04655235 on ClinicalTrials.gov